Atossa Therapeutics Completes Pre-IND Meeting with U.S. Food & Drug Administration
06 déc. 2021 09h15 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and...
Registration Is Now Open For The Tribe Public Webinar Event On November 30, 2021 “A Town Hall Q&A Event With Atossa Therapeutics Management Team”
24 nov. 2021 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
Atossa Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update
15 nov. 2021 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and...
Atossa Therapeutics CEO Dr. Steven Quay Emphasizes Importance of Breast Cancer Screening During Breast Cancer Awareness Month
21 oct. 2021 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Dr. Steven Quay, CEO of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative...
Atossa Therapeutics Begins Enrollment in Clinical Study of AT-H201 in Australia
30 sept. 2021 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote
07 sept. 2021 17h20 HE
|
Atossa Therapeutics, Inc.
Leading proxy advisory firms ISS and Glass Lewis recommend voting in favor Atossa establishes intended criteria for non-use of additional shares for financing transactions SEATTLE, Sept. 07, 2021 ...
Atossa Therapeutics Receives Approval from the Swedish Ethics Review Authority to Initiate a Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density in Sweden
02 sept. 2021 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder Meeting
13 août 2021 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and...
Atossa Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9-10, 2021
05 août 2021 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Receives Regulatory Approval To Open Clinical Study of AT-H201 in Australia
07 juil. 2021 09h30 HE
|
Atossa Therapeutics, Inc.
Nebulized formulation being developed to improve lung function in both active-disease COVID-19 patients and “Long Haul” patients with post-infection pulmonary disease SEATTLE, July 07, 2021 (GLOBE...